XANTO GROUP represents a U.S.-based pharmaceutical laboratory and encompasses within its structure several affiliated companies, including LANZES GENETICS S.A., which is responsible for pharmaceutical distribution activities across international markets.
Our group offers innovative products licensed by the U.S. Food and Drug Administration (FDA) and is currently undergoing the regulatory process with the European Medicines Agency (EMA) to expand our reach into the European market under full compliance.
DRUGS
NEXT-GEN WEIGHT CONTROL PHARMACEUTICALS
We offer the most effective anti-obesity medications available today, developed under rigorous international pharmaceutical standards and distributed globally through our authorized entities.
PESO CERO S3
(Semaglutide + Niacinamide (B3))
PESO CERO S3 is an advanced formulation designed for obesity management and metabolic balance. It combines semaglutide, a GLP-1 receptor analogue that reduces appetite and improves glucose regulation, with niacinamide (vitamin B3), which supports energy balance and lipid metabolism.
Available in injectable and oral tablet forms, with presentations suitable for 15-day treatments and long-term use under medical supervision.
PESO CERO T3
(Tirzepatide + Niacinamide (B3))
PESO CERO T3 represents a new generation of combination therapies for body weight management and metabolic optimization. Its composition, based on tirzepatide, acts on dual GIP and GLP-1 receptors to enhance weight loss and glycemic control, while niacinamide (vitamin B3) supports cellular function and energy utilization.
It is recommended as part of a balanced diet and an active lifestyle, under professional medical guidance.